$20.69
-0.78 (-3.63%)
Open$21.30
Previous Close$21.47
Day High$21.30
Day Low$20.41
52W High$44.00
52W Low$21.72
Volume—
Avg Volume22.7K
Market Cap106.37M
P/E Ratio—
EPS$-1.06
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+62.2% upside
Current
$20.69
$20.69
Target
$33.56
$33.56
$24.17
$33.56 avg
$46.23
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 687.2K | 1.09M | 10.43M |
| Net Income | -12,476,417 | -17,738,981 | 2.46M |
| Profit Margin | -1,815.3% | -1,724.6% | 23.6% |
| EBITDA | -16,273,435 | -24,423,006 | 3.49M |
| Free Cash Flow | — | — | 3.25M |
| Rev Growth | -36.7% | -36.7% | +12.7% |
| Debt/Equity | — | — | 1.45 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $295.03 | +0.20% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $465.67 | -0.30% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $168.08 | +0.08% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $538.60 | -0.74% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $955.47 | +0.45% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $165.04 | +5.36% | 7.7 | 20.98B |